{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:56:01Z","timestamp":1791179761961,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Almost 5% of pregnancies are affected by immune\u2010mediated inflammatory diseases (IMIDs). As treatments become available, understanding their use during pregnancy is important. We aimed to describe maternal, pregnancy and infant outcomes among IMID pregnancies exposed to biologic therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the Merative\u2122 MarketScan\u00ae Commercial Database, we identified pregnancies among mothers aged 15\u201345 with a pre\u2010gestational IMID diagnosis. Biologic exposure during pregnancy was ascertained using prescription and procedure claims and classified by trimester. Outcomes included maternal complications, fetal\/neonatal outcomes and pregnancy loss. Descriptive statistics were used to summarize characteristics, comorbidities, medication use and outcomes by biologic exposure status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 257\u2009409 IMID pregnancies, 6531 (2.5%) were exposed to biologics. Biologic\u2010exposed pregnancies more frequently involved multiple IMIDs (34.9%\n                      <jats:italic>vs<\/jats:italic>\n                      . 7.7%). Nearly half of tumour necrosis factor inhibitor (TNFi) exposures occurred across all trimesters, while first\u2010trimester\u2010only exposure was more common for several non\u2010TNFi biologics. Live births occurred in 77.4% of biologic\u2010exposed pregnancies and 74.2% of biologic\u2010unexposed pregnancies, with most births occurring at term. Maternal serious infections (i.e., infections requiring hospitalization) occurred in 19.7% of biologic\u2010exposed pregnancies and 16.5% of unexposed pregnancies. Among 2066 biologic\u2010exposed infants, the proportions of low birth weight and neonatal intensive care unit admission varied by specific non\u2010TNFi biologics, whereas the distribution of neonatal outcomes appeared similar across exposure groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Biologic use in IMID pregnancy increased over time and extended beyond the first trimester. Pregnancies with biologic exposure differed from unexposed pregnancies in disease characteristics and treatment patterns. Maternal and neonatal outcomes varied across biologic exposure groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70848","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:50:42Z","timestamp":1791179442000},"source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of pregnancy and birth outcomes following biologic exposure in immune\u2010mediated inflammatory diseases: A population\u2010based study"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3719-1248","authenticated-orcid":false,"given":"Leah K.","family":"Flatman","sequence":"first","affiliation":[{"name":"Centre de Recherche Azrieli du Centre Hospitalier Universitaire Sainte\u2010Justine  Montreal Quebec Canada"},{"name":"Faculty of Pharmacy Universit\u00e9 de Montr\u00e9al  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4151-8960","authenticated-orcid":false,"given":"Lisiane F.","family":"Leal","sequence":"additional","affiliation":[{"name":"Centre de Recherche Azrieli du Centre Hospitalier Universitaire Sainte\u2010Justine  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0999-3272","authenticated-orcid":false,"given":"Gabra","family":"Nohmie","sequence":"additional","affiliation":[{"name":"Centre de Recherche Azrieli du Centre Hospitalier Universitaire Sainte\u2010Justine  Montreal Quebec Canada"},{"name":"Faculty of Pharmacy Universit\u00e9 de Montr\u00e9al  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7535-5517","authenticated-orcid":false,"given":"Anick","family":"B\u00e9rard","sequence":"additional","affiliation":[{"name":"Centre de Recherche Azrieli du Centre Hospitalier Universitaire Sainte\u2010Justine  Montreal Quebec Canada"},{"name":"Faculty of Pharmacy Universit\u00e9 de Montr\u00e9al  Montreal Quebec Canada"},{"name":"Faculty of Medicine Universit\u00e9 Claude Bernard Lyon 1  Lyon France"},{"name":"Faculty of Medicine Universit\u00e9 Paris Cit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2019.03.003"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665\u20109913(25)00039\u20106"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741\u20107015\u201011\u201088"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103301"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577\u2010021\u201000603\u20101"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.02.023"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.02.021"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.10504"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1608403"},{"key":"e_1_2_9_11_1","unstructured":"Merative Merative MarketScan Research Databases. Retrieved October 28 2025 https:\/\/www.merative.com\/documents\/merative-marketscan-research-databases"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475\u20106773.2006.00635.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3284"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5633"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1101\/2022.12.13.22283418"},{"key":"e_1_2_9_16_1","unstructured":"World Health Organization (WHO) International Statistical Classification of Diseases and Related Health Problems (ICD). Retrieved December 8 2025 https:\/\/www.who.int\/standards\/classifications\/classification-of-diseases"},{"key":"e_1_2_9_17_1","first-page":"62","volume-title":"Basic & Clinical Pharmacology","author":"Holford NHG","year":"2021"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3233\/NPM\u2010230014"},{"key":"e_1_2_9_19_1","unstructured":"R Core Team R: A Language and Environment for Statistical Computing Version 4.4.3 R Foundation for Statistical Computing 2025 https:\/\/www.R-project.org\/"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70229"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916\u2010024\u201003309\u2010y"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103331"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2025\u20100048"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ero.2025.06.011"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30210"},{"key":"e_1_2_9_26_1","volume-title":"Births: Final Data for 2023","author":"Osterman MJK","year":"2023"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4261"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404\u2010022\u201006463\u2010x"},{"key":"e_1_2_9_29_1","unstructured":"Kaiser Family Foundation Medicaid State Fact Sheets. Retrieved January 20 2026 https:\/\/www.kff.org\/interactive\/medicaid-state-fact-sheets\/"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70848","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70848","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:50:44Z","timestamp":1791179444000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,4]]},"references-count":28,"alternative-id":["10.1002\/bcp.70848"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70848","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,4]]},"article-number":"bcp.70848"}}